Saturday, February 14, 2026 2/14/2026

IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY

Award Number: U01AI056435
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2003
PERIOD OF PERFORMANCE END DATE: 03/31/2006

Group Awards By:

View Award Description

IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY - DESCRIPTION (provided by applicant): Synthetic oligonucleotides with immunostimulatory sequences (ISS) containing unmethylated CpG dinucleotides mimic the innate recognition of microbial DNA and show great promise as adjuvants and immune modulators in a wide variety of therapeutic settings. In addition to their ability to activate multiple components of innate immunity, ISS have shown the ability to "prime" the innate immune system to give enhanced innate and subsequent adaptive responses to a number of bacterial and viral pathogens (3). This can lead to enhanced resistance to both lethal and sublethal challenges. A single administration of ISS in animal models can provide measurable protection for two to four weeks and increased resistance can be maintained with periodic administration of ISS. Prophylactic vaccination through the innate immune system has significant potential as a first-line defense for populations threatened with exposure to bioterrorism/biowarfare agents or exotic or emerging infectious diseases. This proposal is for the development of an inhaled form of ISS as a prophylaxis for airborne infectious agents. We currently are developing 1018 ISS for treatment of asthma and have completed preclinical development and Phase I safety studies in man. The current studies would provide a set of proof-of-principle studies for its use as an inhaled prophylactic and would generate a set of surrogate assays that would be essential for clinical development for this indication.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $759,577 )
2004	2004	DYNAVAX TECHNOLOGIES CORPORATION	717 POTTER STREET SUITE 100	BERKELEY	CA	94710	ALAMEDA	USA	Allergy and Infectious Diseases Research	000	2	5/24/2004	NON-COMPETING CONTINUATION	$759,577
														Subtotal = $759,577

Issue Date FY: 2003 ( Subtotal = $739,815 )
2003	2003	DYNAVAX TECHNOLOGIES CORPORATION	717 POTTER STREET SUITE 100	BERKELEY	CA	94710	ALAMEDA	USA	Allergy and Infectious Diseases Research	000	1	9/29/2003	NEW	$739,815
														Subtotal = $739,815

Grand Total All Awards = $1,499,392

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY

Award Number: U01AI056435

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2003

PERIOD OF PERFORMANCE END DATE: 03/31/2006

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer